Acute urine retention induced by ceftriaxone

• Published in: Saudi journal of kidney diseases and transplantation Vol. 22; no. 6; pp. 1226 - 1228
• Main Authors: Aql, Kamal F., Misri, Amirah T., Hjazeen, Maali M.
• Format: Journal Article
• Language: English
• Published: Riyadh, Saudi Arabia Saudi Center for Organ Transplantation 01.11.2011; Medknow Publications and Media Pvt. Ltd; Wolters Kluwer Medknow Publications
• Subjects: Acute Disease; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; Ceftriaxone; Ceftriaxone - adverse effects; Ceftriaxone - therapeutic use; Ceftriaxone sodium; Child, Preschool; Complications and side effects; Humans; Male; Meningitis - drug therapy; Retention; Uric Acid - urine; Urinary Retention - chemically induced; Urine; الاستسقاء; المرضى; سيفترياكسون; غسيل الكلى; Saudi Arabia
• ISSN: 1319-2442; 2320-3838

This study was conducted to assess the current practice patterns of care for hemodialysis (HD) patients at the Jordan University Hospital Dialysis Center using Dialysis Outcomes Quality Initiative Guidelines as the reference. In a cross-sectional study, we assessed 61 patients on HD. The Kt / V were calculated, and data on serum levels of hemoglobin, iron, ferritin, transferrin saturation, calcium, phosphate, and intact parathormone (PTH) were collected. The values were compared with the dialysis outcomes quality initiative (K / DOQI) recommended target values. Fortyone patients (67.2%) had an arteriovenous fistula as the primary access. The mean hemoglobin level was 10.8 ± 1.4 g/dL, 9.8% of patients had mean serum ferritin < 100 ng /dL and 14.7 % had transferrin saturation < 20 %. The mean serum calcium level was 9.1 ± 0.9 mg / dL and serum calcium level between 8.5 and 10.5 mg / dL was found in 82 % of HD patients. The mean serum phosphorus was 3.9 ± 1.1 mg/dL and 59% of patients had serum phosphorus between 3.5 and 5.5 mg / dL. The mean serum PTH was 364 ± 315 and 14 patients (23 %) had serum PTH between 150 and 300 pg / mL. The achieved standard of HD among our study patients was acceptable and, in many aspects, comparable with the NKF-KDOQI guidelines. However, there is still need to improve the management of anemia and control of hyperparathyroidism.